Express Pharma
Home  »  Latest Updates  »  Cipla receives US FDA approval for generic Epzicom tabs

Cipla receives US FDA approval for generic Epzicom tabs

13

The tablets in combination with other antiretroviral agents are used for the treatment of HIV-1 infection

Cipla received final approval for its ANDA for Abacavir and Lamivudine tablets USP, 600 mg/300 mg, from the US FDA.

Abacavir and Lamivudine tablets USP, 600 mg/300 mg, are AB-rated generic equivalents to the reference listed drug (RLD), Epzicom tablets, 600 mg/300 mg of ViiV Healthcare Company and are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Epzicom tablets had US sales of approximately $346.3 million for the 12 month period ending February 2017, according to IMS Health. The product will cater to the US market and will be commercially available shortly.

Comments are closed.